

# Nicasio Mancini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7485796/publications.pdf>

Version: 2024-02-01

101  
papers

3,579  
citations

168829

31  
h-index

190340

53  
g-index

108  
all docs

108  
docs citations

108  
times ranked

6534  
citing authors

#	ARTICLE	IF	CITATIONS
1	Maturation signatures of conventional dendritic cell subtypes in COVID-19 suggest direct viral sensing. <i>European Journal of Immunology</i> , 2022, 52, 109-122.	1.6	22
2	COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. <i>Molecular Therapy</i> , 2022, 30, 311-326.	3.7	54
3	SARS-CoV-2 infection despite high levels of vaccine-induced anti-Receptor-Binding-Domain antibodies: a study on 1110 health-care professionals from a northern Italian university hospital. <i>Clinical Microbiology and Infection</i> , 2022, 28, 305-307.	2.8	5
4	Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. <i>Nature Immunology</i> , 2022, 23, 275-286.	7.0	95
5	Nanopore ReCappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs. <i>Nucleic Acids Research</i> , 2022, 50, 3475-3489.	6.5	12
6	Monoclonal Antibodies and Flaviviruses: a Possible Option?. <i>MBio</i> , 2022, 13, e0082422.	1.8	1
7	Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. <i>Cell Reports</i> , 2022, 39, 110859.	2.9	13
8	Reply to: Hultström et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. <i>Mannose-binding lectin genetics in COVID-19. Nature Immunology</i> , 2022, 23, 865-867.	7.0	4
9	Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases. <i>Vaccines</i> , 2022, 10, 801.	2.1	13
10	Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1232.	1.5	2
11	Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects. <i>Journal of Medical Virology</i> , 2021, 93, 2160-2167.	2.5	52
12	A case of psoriatic arthritis triggered by SARS-CoV-2 infection. <i>Rheumatology</i> , 2021, 60, e21-e23.	0.9	45
13	Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro. <i>Pharmacological Research</i> , 2021, 163, 105255.	3.1	88
14	Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials. <i>Emerging Microbes and Infections</i> , 2021, 10, 206-209.	3.0	74
15	Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. <i>Vaccines</i> , 2021, 9, 291.	2.1	11
16	Viral Respiratory Pathogens and Lung Injury. <i>Clinical Microbiology Reviews</i> , 2021, 34, .	5.7	76
17	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. <i>Viruses</i> , 2021, 13, 1514.	1.5	12
18	The interferon landscape along the respiratory tract impacts the severity of COVID-19. <i>Cell</i> , 2021, 184, 4953-4968.e16.	13.5	165

#	ARTICLE	IF	CITATIONS
19	Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. <i>PLoS Pathogens</i> , 2021, 17, e1009878.	2.1	52
20	Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects. <i>Clinica Chimica Acta</i> , 2021, 522, 144-151.	0.5	28
21	Very high SARS-CoV-2 load at the emergency department presentation strongly predicts the risk of admission to the intensive care unit and death. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e247-e250.	1.4	5
22	In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples. <i>Antibiotics</i> , 2021, 10, 1309.	1.5	3
23	A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 6140-6156.	1.9	10
24	Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 772239.	2.2	18
25	Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine. <i>Vaccines</i> , 2021, 9, 1357.	2.1	24
26	Differential Composition of Vaginal Microbiome, but Not of Seminal Microbiome, Is Associated With Successful Intrauterine Insemination in Couples With Idiopathic Infertility: A Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz525.	0.4	31
27	Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. <i>Frontiers in Microbiology</i> , 2020, 11, 1704.	1.5	18
28	Oral and Fecal Microbiota in Lynch Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 2735.	1.0	10
29	Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity. <i>Science Advances</i> , 2020, 6, eabb5938.	4.7	29
30	Type III interferons disrupt the lung epithelial barrier upon viral recognition. <i>Science</i> , 2020, 369, 706-712.	6.0	301
31	Interferon- $\beta$ -1a Inhibition of Severe Acute Respiratory Syndrome "Coronavirus 2 In Vitro When Administered After Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 222, 722-725.	1.9	61
32	Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients. <i>European Urology Oncology</i> , 2020, 3, 784-788.	2.6	41
33	Semen infections in men with primary infertility in the real-life setting. <i>Fertility and Sterility</i> , 2020, 113, 1174-1182.	0.5	29
34	Microbiome studies in the medical sciences and the need for closer multidisciplinary interplay. <i>Science Signaling</i> , 2020, 13, .	1.6	4
35	Lower nasopharyngeal viral load during the latest phase of COVID-19 pandemic in a Northern Italy University Hospital. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1573-1577.	1.4	26
36	IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 2009-2016.	1.4	38

#	ARTICLE	IF	CITATIONS
37	Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects. <i>Journal of Virology</i> , 2019, 93, .	1.5	21
38	Nanosphere's Verigene® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance. <i>Clinical Hematology International</i> , 2019, 1, 120-123.	0.7	2
39	Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle. <i>Antiviral Research</i> , 2018, 151, 71-77.	1.9	9
40	Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients. <i>Bone Marrow Transplantation</i> , 2018, 53, 410-416.	1.3	10
41	Analysis of the Enteric Microbiome: First Tentative Steps Towards a Comprehensive Work-up of Prostate Cancer?. <i>European Urology</i> , 2018, 74, 583-584.	0.9	4
42	Autoimmune hepatitis and occult HCV infection: A prospective single-centre clinical study. <i>Autoimmunity Reviews</i> , 2017, 16, 323-325.	2.5	6
43	Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge. <i>Antiviral Research</i> , 2017, 143, 48-61.	1.9	9
44	A Biologically-validated HCV E1E2 Heterodimer Structural Model. <i>Scientific Reports</i> , 2017, 7, 214.	1.6	32
45	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. <i>Viruses</i> , 2016, 8, 128.	1.5	2
46	Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. <i>Gut</i> , 2016, 65, 512-523.	6.1	67
47	Rational Dosing Strategies of Colistin: What About Resistance?. <i>Clinical Infectious Diseases</i> , 2016, 62, 1054.1-1054.	2.9	2
48	Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes. <i>Drug Discovery Today</i> , 2016, 21, 682-691.	3.2	16
49	Evaluation of resistance against bacterial microleakage of a new conical implant-abutment connection versus conventional connections: an in vitro study. <i>New Microbiologica</i> , 2016, 39, 49-56.	0.1	19
50	Heterosubtypic Protection Conferred by the Human Monoclonal Antibody PN-SIA28 against Influenza A Virus Lethal Infections in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2647-2653.	1.4	2
51	Virus-induced preferential antibody gene-usage and its importance in humoral autoimmunity. <i>Seminars in Immunology</i> , 2015, 27, 138-143.	2.7	13
52	Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections. <i>Future Microbiology</i> , 2015, 10, 665-682.	1.0	7
53	Microbiological Diagnosis of Sepsis: The Confounding Effects of a "Gold Standard". <i>Methods in Molecular Biology</i> , 2015, 1237, 1-4.	0.4	6
54	Potential Impact of a Microarray-Based Nucleic Acid Assay for Rapid Detection of Gram-Negative Bacteria and Resistance Markers in Positive Blood Cultures. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1242-1245.	1.8	67

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of blood culture and a multiplex real-time PCR in hematological patients with suspected sepsis: an observational propensity score-matched study. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 623-632.	1.5	8
56	Epitope Mapping by Epitope Excision, Hydrogen/Deuterium Exchange, and Peptide-Panning Techniques Combined with In Silico Analysis. <i>Methods in Molecular Biology</i> , 2014, 1131, 427-446.	0.4	7
57	HCV E2 core structures and mAbs: something is still missing. <i>Drug Discovery Today</i> , 2014, 19, 1964-1970.	3.2	27
58	Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy. <i>Antiviral Research</i> , 2014, 108, 94-103.	1.9	13
59	Acute respiratory distress in a neutropenic febrile patient after hematopoietic cell transplantation. <i>Journal of Clinical Virology</i> , 2013, 57, 1-4.	1.6	2
60	Characterization of epitopes recognized by monoclonal antibodies: experimental approaches supported by freely accessible bioinformatic tools. <i>Drug Discovery Today</i> , 2013, 18, 464-471.	3.2	32
61	Comparative Evaluation of the Bruker Biotyper and Vitek MS Matrix-Assisted Laser Desorption Ionization-Time Of Flight (MALDI-TOF) Mass Spectrometry Systems for Identification of Yeasts of Medical Importance. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2453-2457.	1.8	79
62	A closer look at prion strains. <i>Prion</i> , 2013, 7, 99-108.	0.9	38
63	Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections. <i>BioMed Research International</i> , 2013, 2013, 1-21.	0.9	15
64	Risks of "Blind" Automated Identification Systems in Medical Microbiology. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3911-3911.	1.8	3
65	Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-12.	3.3	43
66	JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11.	3.3	16
67	Influenza B-Cells Protective Epitope Characterization: A Passkey for the Rational Design of New Broad-Range Anti-Influenza Vaccines. <i>Viruses</i> , 2012, 4, 3090-3108.	1.5	10
68	HCV Proteins and Immunoglobulin Variable Gene (IgV) Subfamilies in HCV-Induced Type II Mixed Cryoglobulinemia: A Concurrent Pathogenetic Role. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	15
69	Molecular Signatures of Hepatitis C Virus (HCV)-Induced Type II Mixed Cryoglobulinemia (MCII). <i>Viruses</i> , 2012, 4, 2924-2944.	1.5	16
70	Potential role of the detection of enterobacterial DNA in blood for the management of neonatal necrotizing enterocolitis. <i>Journal of Medical Microbiology</i> , 2012, 61, 1465-1472.	0.7	8
71	Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. <i>Antiviral Research</i> , 2012, 96, 82-89.	1.9	27
72	Phage Display-based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed against Human Pathogens. <i>International Journal of Molecular Sciences</i> , 2012, 13, 8273-8292.	1.8	37

#	ARTICLE	IF	CITATIONS
73	A Non-VH1-69 Heterosubtypic Neutralizing Human Monoclonal Antibody Protects Mice against H1N1 and H5N1 Viruses. PLoS ONE, 2012, 7, e34415.	1.1	46
74	A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. New Microbiologica, 2012, 35, 289-94.	0.1	20
75	Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein. New Microbiologica, 2012, 35, 475-9.	0.1	8
76	A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Research, 2011, 92, 15-26.	1.9	38
77	A Human Monoclonal Antibody with Neutralizing Activity against Highly Divergent Influenza Subtypes. PLoS ONE, 2011, 6, e28001.	1.1	49
78	Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology, 2010, 399, 144-152.	1.1	40
79	The Era of Molecular and Other Non-Culture-Based Methods in Diagnosis of Sepsis. Clinical Microbiology Reviews, 2010, 23, 235-251.	5.7	318
80	Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes. PLoS ONE, 2009, 4, e8254.	1.1	64
81	Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic Plaques. Journal of Immunology, 2009, 183, 2537-2544.	0.4	27
82	Molecular Diagnosis of Polymicrobial Sepsis. Journal of Clinical Microbiology, 2009, 47, 1274-1275.	1.8	23
83	Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiologica, 2009, 32, 319-24.	0.1	22
84	Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmunity Reviews, 2008, 7, 468-472.	2.5	33
85	Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. Journal of Hepatology, 2008, 49, 299-300.	1.8	26
86	Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein. Journal of Virology, 2008, 82, 1047-1052.	1.5	119
87	Molecular diagnosis of sepsis in neutropenic patients with haematological malignancies. Journal of Medical Microbiology, 2008, 57, 601-604.	0.7	134
88	Anti-HIV-1 Response Elicited in Rabbits by Anti-Idiotypic Monoclonal Antibodies Mimicking the CD4-Binding Site. PLoS ONE, 2008, 3, e3423.	1.1	21
89	Development and validation of a molecular method for the diagnosis of medically important fungal infections. New Microbiologica, 2007, 30, 308-12.	0.1	17
90	Quantitation of Bacillus clausii in biological samples by real-time polymerase chain reaction. Journal of Microbiological Methods, 2006, 65, 632-636.	0.7	5

#	ARTICLE	IF	CITATIONS
91	Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient. <i>Molecular Immunology</i> , 2006, 43, 1363-1369.	1.0	4
92	Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. <i>Journal of Medical Virology</i> , 2006, 78, 1304-1311.	2.5	8
93	Rapid molecular identification of fungal pathogens in corneal samples from suspected keratomycosis cases. <i>Journal of Medical Microbiology</i> , 2006, 55, 1505-1509.	0.7	19
94	Molecular Mycological Diagnosis and Correct Antimycotic Treatments. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3584-3585.	1.8	6
95	Direct sequencing of <i>Scedosporium apiospermum</i> DNA in the diagnosis of a case of keratitis. <i>Journal of Medical Microbiology</i> , 2005, 54, 897-900.	0.7	18
96	<i>Coronaviridae</i> and SARS-associated Coronavirus Strain HSR1. <i>Emerging Infectious Diseases</i> , 2004, 10, 413-418.	2.0	127
97	Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. <i>Virology</i> , 2004, 327, 242-248.	1.1	28
98	Diverging Effects of Human Recombinant Anti-Hepatitis C Virus (HCV) Antibody Fragments Derived from a Single Patient on the Infectivity of a Vesicular Stomatitis Virus/HCV Pseudotype. <i>Journal of Virology</i> , 2002, 76, 11775-11779.	1.5	27
99	A novel expression vector for production of epitope-tagged recombinant Fab fragments in bacteria. <i>Human Antibodies</i> , 2001, 10, 149-154.	0.6	3
100	Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs. <i>Virology</i> , 2001, 288, 29-35.	1.1	38
101	Mapping B-Cell Epitopes of Hepatitis C Virus E2 Glycoprotein Using Human Monoclonal Antibodies from Phage Display Libraries. <i>Journal of Virology</i> , 2001, 75, 9986-9990.	1.5	45